Peerview Neuroscience & Psychiatry Cme/cne/cpe Audio Podcast

Informações:

Synopsis

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Episodes

  • Karl E. Anderson, MD - Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy

    02/06/2021 Duration: 31min

    Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Describe evidence-based interventions for AHP, including the rationale and trial data for recently approved siRNA therapy, Apply evidence-based diagnostic and treatment approaches to minimize disease impact and burden for individuals with AHP.

  • Edward J. Fox, MD, PhD - A Visual Guide to B-Cell Therapies in Relapsing MS: Clarifying the Options in an Expanding Treatment Landscape

    07/05/2021 Duration: 26min

    Go online to PeerView.com/ZVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in multiple sclerosis discusses the role of B cells in MS pathogenesis and the use of anti-CD20 monoclonal antibodies in the management of relapsing forms of MS. Upon completion of this activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Assess the mechanisms of action, safety, and efficacy of anti-CD20 monoclonal antibodies in the treatment of relapsing forms of MS, Apply best practices and clinical evidence when using B-cell–depleting therapies to optimize outcomes for patients with relapsing MS.

  • Marwan Sabbagh, MD, FAAN, CCRI - Expert Perspectives on the Early Diagnosis of Alzheimer’s Disease and the Promise of Novel Therapies on the Horizon

    05/05/2021 Duration: 01h01min

    Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world’s population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerVi

  • Kristina M. Deligiannidis, MD - Test Your Knowledge: The Evidence for GABA-Modulating Neuroactive Steroids as a New Class of Rapid-Acting Antidepressants

    04/05/2021 Duration: 23min

    Go online to PeerView.com/SZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the use of GABA-modulating neuroactive steroids as rapid-acting antidepressants. Upon completion of this activity, participants should be better able to: Discuss the role of GABAergic dysfunction in PPD and MDD and the rationale for therapeutic targeting of GABA-A receptors with neuroactive steroids; Review the current treatment landscape and unmet needs of patients with MDD; Identify key barriers to the diagnosis and management of PPD; Apply recent evidence on the efficacy and safety of approved and emerging neuroactive steroids to the management of patients with PPD and MDD.

  • Anne H. Cross, MD, FAAN / Prof. Xavier Montalban - Exploring the Rationale, Results, and Real-World Clinical Potential of BTK Inhibitors in the Management of Multiple Sclerosis

    22/02/2021 Duration: 49min

    Go online to PeerView.com/BTV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple sclerosis (MS) is associated with complex pathophysiology and numerous management challenges, resulting in the need for a full and diverse range of treatment options. Bruton tyrosine kinase (BTK) inhibitors hinder actions of B cells and resident CNS innate immune cells (microglia) that can contribute to neuroinflammation and neurodegeneration and ultimately lead to disease progression and disability. Based on these mechanisms, BTK inhibitors have the potential to improve outcomes related to inflammation and neurodegeneration. In this PeerView educational activity based on a recent live web broadcast, our experts offer insights into the rationale for using BTK inhibitors to treat MS, current evidence regarding the use of BTK inhibitors in the treatment of MS, and the potential role of BTK inhibitors for individualized MS management based on available evidence and patient

  • Steven Brem, MD - Rethinking Glioblastoma Care in an Evolving Therapeutic Landscape: Expert Perspectives on Modern Modalities, Novel Agents, and Combinations

    17/02/2021 Duration: 01h04min

    Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma mana

  • Maria K. Houtchens, MD, MMs - MS Treatment Decisions Before, During, and After Pregnancy: Focus on the Use of Disease-Modifying Therapies

    10/02/2021 Duration: 38min

    Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

  • John Ravits, MD - Improving Outcomes in ALS Through Early Diagnosis and Emerging Targeted Therapies

    05/02/2021 Duration: 29min

    Go online to PeerView.com/XVB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses early diagnosis and emerging targeted therapies in the treatment of patients with amyotrophic lateral sclerosis (ALS). Upon completion of this activity, participants should be better able to: Apply established criteria to detect and diagnose patients with amyotrophic lateral sclerosis (ALS) early in the disease course, Recognize common genetic mutations that can cause ALS in patients with and without a family history of ALS, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of ALS, Identify the potential impact of emerging therapies on the future management of genetic subtypes of ALS.

  • Bruce Cree, MD, PhD, MAS - Provider Perspectives on Current and Emerging Disease-Modifying Treatments for Multiple Sclerosis

    20/01/2021 Duration: 18min

    Go online to PeerView.com/JFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert neurologist discusses new disease-modifying therapies for multiple sclerosis. Upon completion of this activity, participants should be better able to: Apply the latest efficacy, safety, and tolerability data for approved disease-modifying therapies in individualized management of patients with multiple sclerosis, Discuss emerging data for newly approved disease-modifying therapies for the treatment of multiple sclerosis.

  • Prof. Xavier Montalban - What’s New in Relapsing MS? Expert Perspectives on Pathogenesis, Targeting B Cells for Treatment, and Advances in Disease-State Monitoring

    06/01/2021 Duration: 57min

    Go online to PeerView.com/NXG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances—in understanding of disease pathogenesis, emerging therapies, and new imaging approaches—have the potential to significantly improve care of individuals with multiple sclerosis (MS). The recognition of a central role for B lymphocytes in MS pathogenesis and development of two classes of therapeutic agents that target B cells—anti-CD20 antibodies and Bruton tyrosine kinase (BTK) inhibitors—facilitates the use of more novel disease-modifying therapies (DMTs). In addition, advances in imaging approaches can enhance diagnosis, disease monitoring, and treatment guidance. In this activity, based on a recent live webcast, our expert faculty will offer insight into the pathogenesis of MS, targeting B cells for the treatment of MS, and novel imaging approaches for monitoring disease status and treatment in relapsing MS. Upon completion of this activity, participants should be be

  • Orrin Devinsky, MD - Cannabidiol in the Treatment Arsenal for Severe Epilepsy Syndromes: Practical Guidance for Managed Care Professionals

    06/01/2021 Duration: 01h24min

    Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions t

  • Victor C. Urrutia, MD, FAHA - Not So FAST: Improving the Diagnosis and Treatment of Posterior Circulation Stroke

    03/01/2021 Duration: 32min

    Go online to PeerView.com/NZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert neurologist discusses strategies for accurately diagnosing and treating patients with posterior circulation stroke. After participating in this activity, the learner will demonstrate the ability to: Differentiate the signs and symptoms of acute ischemic posterior circulation stroke from other conditions with which it might be confused, Perform stroke assessments that facilitate more rapid diagnosis of acute ischemic posterior circulation stroke, Compare the therapeutic characteristics of current and emerging thrombolytic agents for acute ischemic stroke.

  • Richard S. Isaacson, MD, FAAN - Advances in the Treatment of Alzheimer’s Disease: Preparing for a Shift in the Treatment Paradigm

    03/01/2021 Duration: 01h05min

    Go online to PeerView.com/JGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the treatment of patients with Alzheimer’s disease. Upon completion of this activity, participants will be able to: Recognize the importance of screening for mild cognitive impairment to identify patients at risk for AD early in the disease course, Employ fluid and imaging biomarkers to make early, etiologically based diagnoses of AD, Assess novel mechanisms of action and clinical data of emerging late-stage treatments that target the underlying pathology of AD, Identify potential infrastructure changes that may be required to prepare for a new AD disease-modifying treatment.

  • Amit Bar-Or, MD, FRCPC / Bruce Cree, MD, PhD, MAS - Realizing the Full Clinical Potential of Sphingosine-1-Phosphate Receptor Modulation to Improve Outcomes in Patients With Multiple Sclerosi

    30/11/2020 Duration: 01h05min

    Go online to PeerView.com/VTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple sclerosis (MS) is a debilitating, chronic inflammatory disease that is characterized by demyelination and neurodegeneration of the central nervous system. Efforts to provide effective treatments for individuals with MS have led to FDA approval of many disease-modifying therapies since 2010, including the sphingosine-1-phosphate receptor (S1PR) modulators. Newer-generation S1PR modulators have been developed to preferentially target receptors 1 and 5, with the goal of improving safety profiles, which is expected to make these agents better treatment options for more MS patients. Moreover, the S1PR modulators have demonstrated a range of therapeutic benefits, including effects on gray matter atrophy. In this activity, based on a recent live webcast, our expert faculty offer insights into the role of S1PRs in the pathophysiology of MS and therapeutic benefits of S1PR modul

  • Peter Goadsby, MD, PhD - Addressing Unmet Needs in the Acute Treatment of Migraine: Focus on the Role of the 5-HT1F Receptor

    19/11/2020 Duration: 32min

    Go online to PeerView.com/JDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert narration is combined with 3D animation, patient video segments, and infographic visuals for an engaging presentation on individualized migraine management, including diagnosis and treatment, the role of 5-HT1F receptor agonists for acute treatment, and consideration of patient perspectives. Upon completion of this activity, participants should be better able to: Identify individuals with migraine, including those who are appropriate candidates for acute treatment, according to current treatment recommendations, Address unmet needs in acute treatment of people with migraine, Evaluate the role of 5-HT1F receptor agonists in meeting individual needs in acute treatment of migraine.

  • Karen Elta Anderson, MD - Finding the Path to Improved Recognition and Management of Tardive Dyskinesia

    03/11/2020 Duration: 58min

    Go online to PeerView.com/EMM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry, neurology, and movement disorders discusses the recognition and management of tardive dyskinesia. Upon completion of this activity, participants should be better able to: Recognize the underlying pathophysiology of tardive dyskinesia, typical symptoms, and the burden on patient quality of life, Apply evidence-based criteria to differentially diagnose tardive dyskinesia from other hyperkinetic movement disorders, Employ the latest clinical evidence on efficacy and safety regarding the use of VMAT2 inhibitors to the management of patients with tardive dyskinesia.

  • Marwan Sabbagh, MD, FAAN, CCRI - Exploring Current Guidelines and Emerging Therapeutic Strategies for the Treatment of Dementia-Related Psychosis

    15/10/2020 Duration: 30min

    Go online to PeerView.com/QCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dementia-related psychosis discusses current guidelines and emerging therapeutic strategies for the treatment of dementia-related psychosis. Upon completion of this activity, participants should be better able to: Employ established tools and current criteria to accurately recognize and diagnose psychosis in patients with dementia, Assess key data sets on the efficacy, safety, and tolerability of available and emerging treatment approaches for the management of dementia-related psychosis (DRP), Select individualized nonpharmacological and/or pharmacological treatments for DRP based on patients’ specific needs and circumstances.

  • Perry Shieh, MD, PhD, FAAN - Ensuring Optimal Management Throughout the Clinical Spectrum of Spinal Muscular Atrophy

    13/10/2020 Duration: 48min

    Go online to PeerView.com/HNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses SMA presentation and progression, the importance of early SMA diagnosis, treatments approved for SMA, recommendations for symptomatic care, and methods for supporting patients with SMA and their caregivers. Upon completion of this activity, participants should be better able to: Recognize the role of newborn screening in overcoming diagnostic delays in spinal muscular atrophy, Apply current data on the efficacy, safety, and tolerability of approved therapies for the treatment of spinal muscular atrophy from infancy through adulthood, Identify how symptomatic monitoring and support may evolve in patients with spinal muscular atrophy over the course of their disease, Employ symptomatic care in conjunction with approved treatments to optimize outcomes in patients with spinal muscular atrophy.

  • Victor C. Urrutia, MD, FAHA - Time Is of The Essence: Incorporating Recent Guideline Updates to Support Early Recognition and Management of Acute Ischemic Stroke

    12/10/2020 Duration: 54min

    Go online to PeerView.com/GMR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discusses current guideline-based recommendations and therapeutic interventions to accurately identify and appropriately manage patients with an acute ischemic stroke. Upon completion of this activity, participants should be better able to: Describe the burden of acute ischemic stroke according to current standards of care from the perspective of the patient and the healthcare system, Identify patients with salvageable brain tissue using newer imaging technologies consistent with recommendations in recently updated evidence-based guidelines, To improve management of acute ischemic stroke, determine appropriate candidates to initiate timely therapeutic interventions in patients with suspected stroke.

  • Gregory W. Albers, MD - Large Hemispheric Infarction: Exploring the Latest Clinical Advances in the Diagnosis and Treatment

    02/10/2020 Duration: 31min

    Go online to PeerView.com/NDJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a stroke and vascular neurologist shares a patient case to provide clinical relevance and a practical exploration of the latest advances in the diagnosis and treatment of patients with a large hemispheric infarction (LHI). Upon completion of this activity, participants should be better able to: Apply current evidence-based guidelines to diagnose and treat patients with an LHI, Identify clinical characteristics associated with increased risk of cerebral edema in patients following an LHI, Summarize the benefits and limitations of current and emerging therapeutic strategies to prevent cerebral edema in patients following an LHI.

page 1 from 3